drugset
drugset / Trial / NCT00742872

Randomized Trial of Mosapride Versus Placebo in the Treatment of Constipation-Predominant Irritable Bowel Syndrome

NCT00742872 ↗

Phase 3 Terminated 41 enrolled American University of Beirut Medical Center
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether Mosapride, an agent which acts on serotonin receptors in the gastrointestinal tract, is effective in the treatment of constipation-predominant irritable bowel syndrome (C-IBS).

Timeline

Start
2008-09
Primary completion
2010-06
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Mosapride Small molecule 5 mg Oral

Indications

irritable bowel syndrome